Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among AQUARIAN HOLDINGS VI L.P., AQUARIAN BEACON MERGER SUB INC., AQUARIAN HOLDINGS LLC (solely for purposes of Section 5.7, Section 6.18, Section 6.19 and Section 9.13) and BRIGHTHOUSE FINANCIAL, INC. Dated as of November 6, 2025 Article I DEFINITIONS 2 Article II THE MERGER 21 Article III EXCHANGE OF SHARES 26 Article IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY 28 i Page Section 1.1 Definitions 2 Section 1.2 Other Definitional and Inte ...

Solo Brands, Inc. Announces Third Quarter 2025 Results Consolidated Third Quarter 2025 Highlights Compared to Third Quarter 2024 Segment Third Quarter 2025 Highlights Compared to Third Quarter 2024 (2) Solo Stove Chubbies Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash Flow Grapevine, Texas, November 6, 2025: Solo Brands, Inc. (NYSE: SBDS) ("Solo Brands" or "the Company") a lea ...

Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. MESA open-label extension trial in adults with Becker: The Company continues to advance MESA, an open-label extension trial that collects long term safety and efficacy data of sevasemten t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) (State or ...

Press Release Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights GAITHERSBURG, Md., November 6, 2025 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025. "We have continued the steady transformation of Novavax and are proud of our progress this quarter." said John C. Jacobs, President and Chief Executive Officer, Novavax. "This year we have relaunched the Company with a focus on R&D and pa ...

Exhibit 99.1 LSI INDUSTRIES REPORTS FISCAL 2026 FIRST QUARTER RESULTS AND DECLARES QUARTERLY CASH DIVIDEND CINCINNATI, November 6, 2025 – LSI Industries Inc. (Nasdaq: LYTS, "LSI" or the "Company") a leading U.S. based manufacturer of commercial lighting and display solutions, today reported financial results for the fiscal 2026 first quarter ended September 30, 2025. The Company declared a regular cash dividend of $0.05 per share payable on November 25, 2025, to shareholders of record on November 17, 2025. ...

Exhibit 99.1 UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum PRINCETON, N.J. November 6, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments. "Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with rec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-38895 South Plains Financial, Inc. (Exact name of registrant as specified in its charter) Texas 75-2453320 5219 ...

Exhibit 99.1 Outlook Guidance for the fiscal year ending June 30, 2026 has been increased and now includes the Curtis acquisition: • Sales were a record $5.1 billion; organic sales growth was 5% • Net income was $808 million, an increase of 16%, or $927 million adjusted, an increase of 14% • EPS were $6.29, an increase of 18%, or a record $7.22 adjusted, an increase of 16% • Segment operating margin was 24.2%, an increase of 160 bps, or 27.4% adjusted, an increase of 170 bps • Cash flow from operations was ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39487 Silence Therapeutics plc (Exact name of registrant as specified in its charter) | England and Wales | ...